Mike has been instrumental in delivering transformative treatments, including multispecific T cell engagers and ADCs, which have set new standards in patient care. Mike played a key role at Genentech/Roche in the development and approval of POLIVY®, and drove the global advancement and approval of LUNSUMIO®. During a prior tenure at Amgen, he led clinical pharmacology strategies for high-profile oncology programs such as IMDELLTRA®, pasotuxizumab, acapatamab, IMLYGIC®, and VECTIBIX®, while shaping the regulatory approach for BLINCYTO® in China.

Earlier in his career, Mike’s ORISE fellowship at the US FDA provided him with invaluable regulatory and model-informed drug-development insights, which he continues to apply to innovative drug development. He holds two patents for T cell engagers (IMDELLTRA® and LUNSUMIO®). He earned his PhD from the University of Washington.